On Oct 31, major Wall Street analysts update their ratings for $Exelixis (EXEL.US)$, with price targets ranging from $29 to $38.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $30.
BofA Securities analyst Jason Gerberry maintains with a buy rating.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $31 to $38.
Wells Fargo analyst Derek Archila maintains with a buy rating, and adjusts the target price from $32 to $36.
TD Cowen analyst Yaron Werber maintains with a buy rating, and maintains the target price at $34.
Furthermore, according to the comprehensive report, the opinions of $Exelixis (EXEL.US)$'s main analysts recently are as follows:
Exelixis' third quarter showed robust performance for Cabometyx, with net product sales exceeding expectations by approximately 8% and achieving 12% growth compared to the previous year. The consistent revenue generation from Cabometyx and the promising prospects of the pipeline, particularly through zanzalintinib, are seen as significant potential contributors to future performance.
Exelixis' third-quarter cabo revenues surpassed expectations, coming in at $478.1 million, which reflects a 4.7% beat over the consensus. This performance is attributed to an uptick in cabo market share and an increase in new patient starts. Concurrently, the management has revised its future net product revenue and total revenue guidance upwards by 5.6% and 7.4% respectively. Despite this positive outlook, a cautious stance is maintained regarding zanza until further late-stage data is available to justify increased estimates.
Here are the latest investment ratings and price targets for $Exelixis (EXEL.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.